Although AML has an extremely low mutational burden19, the overall enrichment of plasma B cells and cross-presenting dendritic cells in tumors may suggest tumor-specific antigen presentation in tumor microenvironment that may include all the genes/proteins highly expressed in AML, including CTSK and MDK. The gene discussed is CTSK; the disease is acute myeloid leukemia.